This paper examines the etiology of asthma, an inflammatory airway disease characterized by recurring symptoms, bronchospasm, and reversible airflow obstruction. The paper discusses the diagnostic criteria, classification systems (atopic versus non-atopic), and acute and preventive treatment approaches. It analyzes the major environmental factors—including air pollution, allergens, and secondhand smoke—that contribute to asthma development and exacerbation. The paper also explores the hygiene hypothesis as an explanation for rising asthma prevalence and examines genetic predisposition through the atopic disease triad. Finally, it outlines contemporary management strategies centered on trigger identification, medication selection, and personalized symptom monitoring plans.
Asthma is an inflammatory disease that affects the airways, characterized by recurring and variable symptoms, bronchospasm, and reversible airflow obstruction. Common symptoms include coughing, shortness of breath, wheezing, and chest tightness. Asthma is understood to result from both environmental and genetic factors. Diagnosis is based on patterns of symptoms and response to therapy over time. Clinical classification relies on the frequency of symptoms and forced expiratory volume in one second (FEV1), as well as peak expiratory flow rates. Asthma is also classified as either non-atopic (intrinsic) or atopic (extrinsic). Atopy refers to a genetic predisposition to the development of type 1 hypersensitivity reactions (Clark, 2010).
Treatment of acute asthma symptoms typically involves inhaled short-acting beta-2 agonists such as salbutamol, often combined with oral corticosteroids. In severe cases, intravenous corticosteroids, magnesium sulfate, and hospitalization may be required. Symptom prevention relies on avoiding triggers—including irritants and allergens—and continuing prescribed inhaled corticosteroids. For patients whose symptoms remain uncontrolled despite inhaled corticosteroids, long-acting beta-2 agonists and anti-leukotriene agents (such as CysLT antagonists or arachidonate 5-lipoxygenase inhibitors) can enhance effectiveness (Murphy, 2011).
Environmental factors significantly influence both the development and exacerbation of asthma. Air pollution, allergens, and various environmental chemicals are major contributors to asthma risk. Maternal smoking during pregnancy and after delivery increases the risk of asthma-like symptoms in children. Higher levels of ozone and traffic pollution are associated with increased asthma severity and development (Douglas & Elward, 2010). The hygiene hypothesis explains the high prevalence of asthma worldwide as an unintended consequence of reduced childhood exposure to non-pathogenic viruses and bacteria.
The hygiene hypothesis proposes that reduced exposure to viruses and bacteria in modern childhood is partly due to increased household cleanliness and smaller family sizes in contemporary societies. The atopic disease triad—characterized by asthma, allergic rhinitis, and atopic eczema—is a well-recognized pattern. Major risk factors for asthma development include a personal or family history of atopic diseases, with asthma occurring at higher rates than hay fever or eczema alone. Asthma is also associated with autoimmune conditions such as Churg-Strauss syndrome, a form of vasculitis, and individuals with certain forms of urticaria frequently experience asthma symptoms (Clark, 2010).
Although asthma is widely recognized clinically, professional understanding continues to evolve. Asthma is defined as a chronic inflammatory disorder of the airways in which multiple cell types and cellular elements play a role. Chronic inflammation leads to airway hyperresponsiveness, resulting in recurrent episodes of wheezing, chest tightness, breathlessness, and early morning or nighttime coughing. These episodes are characterized by variable airflow obstruction within the lungs that is often reversible with appropriate treatment. Understanding this pathophysiology is central to recognizing why asthma is both a chronic condition and one that responds to targeted pharmacological interventions (Clark, 2010).
"Personalized plans, trigger avoidance, and symptom monitoring"
You’re 70% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.